{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Deng Y"],"funding":["Fundamental Research Funds for the Central Universities","Princess Margaret Cancer Foundation","National Natural Science Foundation of China"],"pagination":["e70215"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12330342"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["44(18-19)"],"pubmed_abstract":["Overall survival has been used as the primary endpoint for many randomized trials that aim to examine whether a new treatment is non-inferior to the standard treatment or placebo control. When a new treatment is indeed non-inferior in terms of survival, it may be important to assess other outcomes including health utility. However, analyzing health utility scores in a secondary analysis may have limited power since the primary objectives of the original study design may not include health utility. To comprehensively consider both survival and health utility, we developed a composite endpoint, HUS (Health Utility-adjusted Survival), which combines both survival and utility. HUS has been shown to be able to increase statistical power and potentially reduce the required sample size compared t"],"journal":["Statistics in medicine"],"pubmed_title":["Health Utility Survival for Randomized Clinical Trials: Extensions and Statistical Properties."],"pmcid":["PMC12330342"],"funding_grant_id":["12371264","CXTD14-05","12171329"],"pubmed_authors":["Hao M","Huang SH","de Almeida JR","Xu W","Deng Y","Liu G"],"additional_accession":[]},"is_claimable":false,"name":"Health Utility Survival for Randomized Clinical Trials: Extensions and Statistical Properties.","description":"Overall survival has been used as the primary endpoint for many randomized trials that aim to examine whether a new treatment is non-inferior to the standard treatment or placebo control. When a new treatment is indeed non-inferior in terms of survival, it may be important to assess other outcomes including health utility. However, analyzing health utility scores in a secondary analysis may have limited power since the primary objectives of the original study design may not include health utility. To comprehensively consider both survival and health utility, we developed a composite endpoint, HUS (Health Utility-adjusted Survival), which combines both survival and utility. HUS has been shown to be able to increase statistical power and potentially reduce the required sample size compared t","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Aug","modification":"2026-04-13T08:18:18.082Z","creation":"2026-04-07T13:29:45.651Z"},"accession":"S-EPMC12330342","cross_references":{"pubmed":["40772764"],"doi":["10.1002/sim.70215"]}}